Dr. Birgitta Brunes is a woman who has risen to the top of her profession while maintaining a balance between health goals and client needs. Dr. Brunes is a general practitioner who specializes in treating Multiple Sclerosis. Once diagnosed with MS, she learned to overcome the condition and has devoted her life to helping others make use of her methods of treatment. Having established her own clinic, Brunes Pharm AB, in her native Stockholm, Sweden (1994), she devotes much of her time between patient care and ongoing research in the area as well as in anti-aging, nervous and immune systems. research. Her approach involves an extensive program that provides educational courses, treatment and consultation for MS clients at affordable costs, and she is responsible for all phases of patient care.
While Birgitta continues in her work, Christian Brunes serves as managing director for Brunes Pharm AB, overseeing organization, administration and finance. Ingrid devotes her attention to the development of the company, combining keen business acumen and technical expertise to understand new market trends and adapt new strategies. The clinic began in 1993 with a small and dedicated team of professionals that help facilitate specialized personal care and excellent customer service. Fully incorporated the following year, Brunes Pharm AB has grown rapidly and presently offers various solutions to clients in Sweden and around the world. Dr. Brunes, who has been in recovery for the past fifteen years, brings with her a strong background in the health care field. Her book, “From Multiple Sclerosis to Better Health,” has been translated into the English language but has yet to find a publisher. Having completed her studies in 1975, at Karinlinska Institute at Solna as a Medical Doctor, she has worked for several medical organizations. Her attention to detail has enabled her to make a difference. A member of the Life Extension Foundation, she believes that her success is attributed to being able to listen to her patients as well as to communicate to them effectively. It is that quality of leadership, along with her strategic vision, which has contributed to her success in the field of her choosing. Her book has been published in Germany, Denmark and Sweden. Birgitta Brunes Birgitta Brunes, MD, has MS.
Using her medical expertise and training, Birgitta supervises the treatment offered by Brunes Pharm AB. Are you diagnosed with MS? – We might be able to help... Have you been diagnosed with MS, Multiple sclerosis? Then you have probably searched every corner of the internet, literature and magazines for information about the disease and different treatments. Unfortunately there is no cure as of today, but several medicines that slow down the progression of the disease and different treatments that reduce or stop the symptoms are available. Our treatment - Birgitta Brunes method Brunes Pharm AB works with MS-treatment/rehabilitation since 1994. The doctors that work here have personal experience of MS. We have courses for MS-patients. These are usually 10 days on a small conference centre in the countryside 1.5 hour-drive from Stockholm. We work with psychological factors (feelings, stress etc.), social factors and medical treatment. These three factors are combined into an individual treatment plan. After the course you can continue the medical treatment with the doctor you have been treated by during the course.
MS-theory Theory Our theory is founded on the conviction that MS is the result of a lack of neurotransmitters and caused by several factors. This shortage can be accentuated by: 1. Metal toxaemia (e.g. amalgam, welding, etc.) 2. Genetic factors 3. Psychological factors (often trigger factors) stress, demands and “musts”. Background Nerve signals are in part transmitted electrically via nerve fibre and in part bio-chemically via nerve junctions (synapses). The bio-chemical changeover is handled via neurotransmitters. With MS, the casing (myelin) around the nerve fibre is damaged in some places, although the nerve itself is generally undamaged. Scar tissue in the myelin allows the nerve signal to “leak out” and results in too little of the original signal being transmitted. My theory is that if it is possible to amplify the signal then a stronger signal will reach its destination despite the leakage from the myelin sheath. The signal can be amplified using medicines with an effect on neurotransmitters. It is clear that the neurotransmitters must exist in a given relationship to each other for the nerve signals to travel correctly. When this relationship is altered it results in neurological symptoms.
These frequently manifest themselves in numbness or other sensory disturbances, vision problems, fatigue, lack of strength, constipation/diarrhoea, a frequent need to urinate or difficulty in evacuating the bladder which is often accompanied by residual urine. Given the above it is understandable that treatment must be related to variations in the levels of the different neurotransmitters. Initially, different patients have shortages of different neurotransmitters and consequently must be treated according to an individually tailored program. No side affects occur when the medications are taken as prescribed. The patient ingests substances that are in short supply. This is comparable to a diabetic who takes the correct amount of insulin and does not suffer any side effects. My experience suggests that after a period of medication, the body can provide the needed increase in neurotransmitter production, and consequently the use of medicines can be gradually eliminated.
At this stage I generally recommend an increase in the consumption of a variety of amino acids, which are the building blocks of neurotransmitters. Normal neurotransmitter production is not sufficient. A higher level of neurotransmitters is essential to amplify the nerve impulses so they can pass through the nerve fibre despite the damaged myelin sheath. The patient also needs to conserve the neurotransmitters that exist since they are required for all bodily activities including thinking, movement, anxiety and stress. It is possible to preserve neurotransmitters by resting a great deal and by engaging in activities that heighten well-being. I believe, for example, that it is a shame and unnecessary when patients deplete their small stock of neurotransmitters by climbing stairs, engaging in physical training and even making beds for their family members. Read more – reference 4 » When one has reached a reasonable level of well-being via medicines and rest there is a temptation to start living a “normal” life. You wake up one morning and feel more energetic than you have for a long time and the ambitious ego starts doing all of the things that previously had to wait.
The backlash usually comes quickly and relentlessly. I generally warn of this but it appears that everyone has to learn from personal experience. Lifestyle changes take a long time, and new boundaries must be tested with extreme caution. Preferably, one should avoid even approaching the limits. Everything is allowed providing it does not increase symptoms, neither in the short run, nor in the long. There is a strong link between depression and MS. Depression does not appear after being diagnosed with MS; it usually comes first. My clinical experience shows that many MS sufferers have had an unusually troublesome or unpleasant period before the debut of the disease. Read more – reference 5 » We also know that in depressive states the levels of neurotransmitters (primarily noradrenaline and serotonin) decline. It is also known that immune reactions appear during depression. It has recently been established that a shortage of e.g. noradrenaline can also lead to the occurrence of inflammatory reactions in the brain.
Read more – reference 6 » Earlier research also indicates that a reduction has taken place in several of the nervous system's neurotransmitters, particularly noradrenaline and serotonin, in more severe MS cases. Recent research has also indicated a dysfunction in the neurotransmitter acetylcholine. This can result in deficits in the cognitive domains of memory, learning, attention and information processing In other words, the medical aspect of this treatment aims to amplify the nerve impulses by compensating for low neurotransmitter levels or neurotransmitters out of balance. Mercury (Hg80) According to WHO, amalgam fillings are the greatest source of mercury in the body. Amalgam contains about 50% mercury (Hg). Toxic mercury vapours are continually released from amalgam fillings.
Mercury vapours are one of the most powerful known neurotoxins. 1. Mercury hinders the production of neurotransmitters. As a result, the transmission of nerve impulses may be hampered, made impossible or “go wrong”. Symptoms such as the loss of sensitivity, numbness, prickling, tingling etc can arise. Read more— reference 3 » 2. Mercury increases the quantity of free radicals, which in turn lead to oxidation in the body, particularly if there is a shortage of antioxidants. 3. Mercury also settles on sulphur and hydrogen groups, thus disturbing the function of enzymes and membranes. 4. Mercury induces autoimmun responses. NOTE! If you are considering replacing your amalgam fillings with plastic (composite) or ceramic fillings, you must obtain KNOWLEDGE before starting the procedure. During replacement, the released quantity of Hg is unavoidably higher and you risk more serious symptoms. Contact a dentist with lengthy experience in the procedure (particularly with MS patients) and, above all, do the procedure in collaboration with a PHYSICIAN who is knowledgeable and understands the problems that can arise. Contact your local dental association for more information on the replacement of amalgam fillings
.
| < Prev | Next > |
|---|
